Non-imidazole aryloxyalkylamines
OwnerRichard Apodaca, Nicholas I. Carruthers +4inventors
InventorsRichard Apodaca, Nicholas I. Carruthers, Curt A. Dvorak, Dale A. Rudolph, Chandravadan R. Shah, Wei Xiao
Life of this patent
Estimating the term…
Abstract
Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
Claims13
-53. (canceled)
A method of inhibiting histamine H3 receptor activity in a subject, comprising administering an effective amount of a compound of formula (I) to a subject in need of such inhibition of histamine H3 receptor activity, wherein the compound of formula (I) is:
- wherein Ra, and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl, (C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
- n is 0-4;
- one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
- G is a nitrogen-containing group selected from one of the following:
- —OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1 Q)R6R7, —C(L1Q)R6R7,
- wherein:
- L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
- L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
- L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, phenyl, naphthyl, (naphthyl)C1-6 alkylene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
- L4 is C1-5 alkylene,
- L5 is C1-5 alkylene,
- L6 is C1-5 alkylene,
- L7 is C1-5 alkylene or absent;
- Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
- each of R5 and R6 is independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
- R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
- each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
- R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-6 alkylene, or (phenyl) C1-6 alkylene;
- wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
- wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocycyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl)C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
- or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
- L3 is not phenyl or naphthyl.
A method of treating a subject having a disease or condition modulated by histamine H3 receptor activity, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) wherein the compound of formula (I) is:
- wherein Ra and Rb are independently C1-8 alkyl, C alkenyl, C3-8 cycloalkyl,
- (C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
- n is 0-4;
- one of R1, R2, and R3 is G, and the remaining two are hydrogen or halo;
- G is a nitrogen-containing group selected from one of the following:
- —OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
- wherein:
- L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
- L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
- L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
- L4 is C1-5 alkylene;
- L5 is C1-5 alkylene;
- L6 is C1-5 alkylene;
- L7 is C1-5 alkylene or absent;
- Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
- each of R5 and R6 is independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
- R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
- each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
- R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-6 alkylene, or (phenyl) C1-6 alkylene;
- wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
- wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
- or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
- L3 is not phenyl or naphthyl.
A method for treating a disease or condition modulated by at least one receptor selected from the histamine H1 receptor and the histamine H3 receptor, said method comprising (a) administering to a subject a jointly effective amount of a histamine H1 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of formula (I), said method providing a jointly therapeutically effective amount of said compounds, wherein the compound of formula (I) is:
- wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
- (C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
- n is 0-4;
- one of R1, R2, and R3 is G, and the remaining two are hydrogen or halo;
- G is a nitrogen-containing group selected from one of the following:
- —OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
- wherein:
- L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
- L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
- L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
- L4 is C1-5 alkylene;
- L5 is C1-5 alkylene;
- L6 is C1-5 alkylene;
- L7 is C1-5 alkylene or absent;
- Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
- each of R5 and R6 is independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
- R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
- each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
- R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-16 alkylene, or (phenyl) C1-6 alkylene;
- wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
- wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
- or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
- L3 is not phenyl or naphthyl.
A method for treating diseases or conditions modulated by at least one receptor selected from the histamine H2 receptor and the histamine H3 receptor in a subject, comprising (a) administering to the subject a jointly effective amount of a histamine H2 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of formula (I) said method providing a jointly therapeutically effective amount of said compounds, wherein the compound of formula (I) is:
- wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
- (C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
- n is 0-4;
- one of R1, R2, and R3 is G, and the remaining two are hydrogen or halo;
- G is a nitrogen-containing group selected from one of the following:
- —OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
- wherein:
- L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
- L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
- L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
- L4 is C1-5 alkylene;
- L5 is C1-5 alkylene;
- L6 is C1-5 alkylene;
- L7 is C1-5 alkylene or absent;
- Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
- each of R5 and R6 is independently selected from hydrogen C1-8 alkyl C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
- R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
- each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
- R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-6 alkylene, or (phenyl) C1-6 alkylene;
- wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
- wherein substituents of Q can be further selected from carboxamide C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
- or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
- L3 is not phenyl or naphthyl.
A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is:
- wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
- (C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
- n is 0-4;
- one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
- G is a nitrogen-containing group selected from one of the following:
- —OL1Q, -L2Q, —N(L1Q)R5, L3C(L1Q)R6R7, —C(L1Q)R6R7,
- wherein:
- L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-3 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
- L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
- L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
- L4 is C1-5 alkylene;
- L5 is C1-5 alkylene;
- L6 is C1-5 alkylene;
- L7 is C1-5 alkylene or absent;
- Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
- each of R5 and R6 is independently selected from hydrogen C1-8 alkyl, C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
- R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
- each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
- R10 is H, C1-8alkyl, C3-8alkenyl, C3-7cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-6 alkylene, or (phenyl) C1-6 alkylene;
- wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
- wherein substituents of Q can be further selected from carboxamide C2-6 alkyl, heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
- or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
- L3 is not phenyl or naphthyl.
A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is:
- wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
- (C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
- n is 0-4;
- one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
- G is a nitrogen-containing group selected from one of the following:
- —OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
- wherein:
- L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
- L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
- L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
- L4 is C1-5 alkylene;
- L5 is C1-5 alkylene;
- L6 is C1-5 alkylene;
- L7 is C1-5 alkylene or absent,
- Q is —NR8R9 or a non-aromatic C2-15heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
- each of R5 and R6 is independently selected from hydrogen C1-8 alkyl C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
- R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
- each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
- R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-16 alkylene, or (phenyl) C1-6 alkylene;
- wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3alkyl;
- wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
- or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
- L3 is not phenyl or naphthyl.
A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is:
- wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
- (C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
- n is 0-4;
- one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
- G is a nitrogen-containing group selected from one of the following:
- —OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
- wherein:
- L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
- L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
- L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C9-5 heteroaryl;
- L4 is C1-5 alkylene;
- L5 is C1-5 alkylene;
- L6 is C1-5 alkylene;
- L7 is C1-5 alkylene or absent;
- Q is —NR8R9 or a non-aromatic C2-15 heterocyclyl, ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
- each of R5 and R6 is independently selected from hydrogen C1-8 alkyl C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
- R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
- each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
- R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-16 alkylene, or (phenyl) C1-6 alkylene;
- wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3 alkyl;
- wherein substituents of Q can be further selected from carboxamide C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
- or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
- L3 is not phenyl or naphthyl.
A method for treating or preventing upper airway allergic response, nasal congestion, or allergic rhinitis, comprising administering to a subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) is:
- wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
- (C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
- n is 0-4;
- one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
- G is a nitrogen-containing group selected from one of the following:
- —OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1 Q)R6R7, —C(L1 Q)R6R7,
- wherein:
- L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
- L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
- L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
- L4 is C1-5 alkylene;
- L5 is C1-5 alkylene;
- L6 is C1-5 alkylene;
- L7 is C1-5 alkylene or absent,
- Q is —NR8R9 or a non-aromatic C2-15heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
- each of R5 and R6 is independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
- R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
- each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
- R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-16 alkylene, or (phenyl) C1-6 alkylene;
- wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3alkyl;
- wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
- or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
- L3 is not phenyl or naphthyl.
A method for studying disorders mediated by the histamine H3 receptor, comprising using an 18F-labeled compound of formula (I) as a positron emission tomography (PET) molecular probe, wherein the compound of formula (I) is:
- wherein Ra and Rb are independently C1-8 alkyl, C3-8 alkenyl, C3-8 cycloalkyl,
- (C3-8 cycloalkyl) C1-6 alkyl, or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclyl optionally including up to 3 additional heteroatoms;
- n is 0-4;
- one of R1, R2 and R3 is G, and the remaining two are hydrogen or halo;
- G is a nitrogen-containing group selected from one of the following:
- —OL1Q, -L2Q, —N(L1Q)R5, -L3C(L1Q)R6R7, —C(L1Q)R6R7,
- wherein:
- L1 is C2-6 alkylene, C3-8 cycloalkylene, C4-6 alkenylene, C4-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C2-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, or (C2-5 heteroaryloxy)C1-6 alkylene;
- L2 is C1-6 alkylene, C3-8 cycloalkylene, C3-6 alkenylene, C3-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 alkylene, (naphthyl)C1-6 alkylene, (C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or (C1-5 heteroarylthio)C1-6 alkylene;
- L3 is C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C2-5 alkanoyl, (phenyl)C1-6 allene, C1-5 heteroaryl)C1-6 alkylene, (phenoxy)C1-6 alkylene, (C1-5 heteroaryloxy)C1-6 alkylene, or C2-5 heteroaryl;
- L4 is C1-5 alkylene;
- L5 is C1-5 alkylene;
- L6 is C1-5 alkylene;
- L7 is C1-5 alkylene or absent,
- Q is —NR8R9 or a non-aromatic C2-15heterocyclyl ring system containing at least one nitrogen atom and optionally between 1 and 3 additional heteroatoms selected from O, S, and N in each ring;
- each of R5 and R6 is independently selected from hydrogen, C1-8 alkyl C2-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, and (C2-7 heterocyclyl)C1-6 alkylene;
- R7 is H, hydroxyl, halo, C2-6 alkoxy or absent where the carbon linking L6 and L7 (or bonded to R6) participates in a double bond;
- each of R8 and R9 is independently selected from hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, C2-15 heterocyclyl, phenyl, (C2-15 heterocyclyl)C1-6 alkylene, and (phenyl) C1-6 alkylene;
- R10 is H, C1-8 alkyl, C3-8 alkenyl, C3-7 cycloalkyl, (C3-7 cycloalkyl)C1-6 alkylene, (C2-15 heterocyclyl)C1-16 alkylene, or (phenyl) C1-6 alkylene;
- wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be independently and optionally substituted with between 1 and 3 substituents selected from halo, amino, nitro, hydroxyl, and C1-3alkyl;
- wherein substituents of Q can be further selected from carboxamide, C2-6 alkyl, C1-8 heterocyclyl, N(C1-6 alkyl)(C1-8 heterocyclyl), NH(C1-8 heterocyclyl), (C1-8 heterocyclyl) C1-3 alkylene, O(C1-8 heterocyclyl), C1-6 alkoxy, (phenyl)C3-6 cycloalkyl-O—, phenyl, (phenyl) C1-3 alkylene, N(C1-6 alkyl)[(phenyl)C1-3 alkylene], and (phenyl)C1-3 alkylene-O— where each of above heterocyclyl, phenyl, and alkyl groups may be optionally substituted with from 1 to 3 substituents independently selected from halogen, nitro, cyano, and C1-3 alkyl;
- or a pharmaceutically acceptable salt, ester, or amide thereof, provided that when NRaRb is a six-membered heterocyclyl ring system and G is
- L3 is not phenyl or naphthyl.
Dependencies are inferred from the claim text.